arrow
E

Ellen K. Ritchie

Cornell University
H指数:41
被引数:8,091

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis

1b期研究:ABBV-744(一种新型选择性BET抑制剂)作为单药疗法在骨髓纤维化患者中的应用

2026-03-190
OAAI
Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

增强继发性HLH的诊断和预后策略:Weill-Cornell Medicine经验的启示

BLOOD
IF23.1
2024-11-050
PRE
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+selected Cells [Haplo-Cord] Versus Matched Donors)

骨髓纤维化的移植结果: 供体类型的影响 (由CD34选择的细胞 [haplo-cord] 支持的脐带血移植物与匹配的供体)

2024-11-010
PRE
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
2023-05-119
OAAI
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response
2020-10-224
OAAI
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
2020-10-1330
OAAI
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic

冠状病毒疾病2019大流行期间的血液学和肿瘤学临床护理

2020-07-1416
OAAI
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
LEUKEMIA
IF13.4
2020-03-0461
OAAI
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

接受急性髓性白血病强化治疗的老年人的老年评估: CALGB 361006 (联盟) 的报告

2020-01-0139
OA
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension

骨髓增殖性肿瘤相关肺动脉高压患者右心室功能障碍的增量效用

2019-12-0118
OAAI
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
LEUKEMIA
IF13.4
2019-07-3022
OAAI
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
2019-06-0165
OAAI
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
2018-07-2398
OAAI